The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
Access Campaigner Felipe Carvalho sets out what needs to happen so that everyone in need has access to new COVID-19 treatment - no patents, no monopolies and accountability on public funding for medical research. No one left behind!
